Edesa Biotech Q2 net loss widens as R&D spending rises

Edesa Biotech

14/05/2026 21:41

Overview

Canada biopharma firm's Q2 net loss widened on higher R&D and operating expenses

Company advanced preparations for Phase 2 vitiligo study and reported positive respiratory drug data

Outlook

Edesa expects site activations and patient recruitment for vitiligo study to begin midyear 2026

Company anticipates operating expenses will continue to rise as program activity builds

Result Drivers

R&D EXPENSES - Higher research and development costs driven by manufacturing and regulatory preparations for vitiligo and respiratory drug programs

ADMIN COSTS - General and administrative expenses rose due to higher salaries and professional fees

Company press release: ID:nGNX68w7k1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.49
Q2 Net Income
-$4.20 mln
Q2 Operating Expenses
$4.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 40.9% below its May 13 closing price of $15.24

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)